APOC3, apolipoprotein C3, 345

N. diseases: 153; N. variants: 15
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.010 Biomarker disease BEFREE Two peptides from APOC3 and THBS1 are validated by PRM as potential biomarkers for non-invasive diagnosis of colorectal cancer. 31502404 2020
Malignant neoplasm of colon and/or rectum
0.010 Biomarker disease BEFREE Two peptides from APOC3 and THBS1 are validated by PRM as potential biomarkers for non-invasive diagnosis of colorectal cancer. 31502404 2020
CUI: C0001339
Disease: Acute pancreatitis
Acute pancreatitis
0.010 Biomarker disease BEFREE Meanwhile, in the acute pancreatitis model, free fatty acids (FFAs) in the pancreas of Gpihbp1-/- mice were greater than in ApoC3-tg mice. 31570698 2019
CUI: C0039128
Disease: Syphilis
Syphilis
0.010 Biomarker disease BEFREE Biomarker analysis revealed three proteins (Apo-A1, Apo-CIII, CRP) that differed between syphilis and other causes. 31697216 2019
CUI: C0085207
Disease: Gestational Diabetes
Gestational Diabetes
0.010 Biomarker phenotype BEFREE High Apo CIII levels and the Apo CIII/Apo AI, Apo CIII/Apo AII, Apo CIII/Apo CII, and Apo CIII/Apo E ratios are all significant risk factors for the development of type 2 diabetes in women with a previous GDM pregnancy. 29529691 2019
Idiopathic Membranous Glomerulonephritis
0.010 Biomarker disease BEFREE Our findings indicate that lipid metabolism, including cholesterol metabolism and arachidonic acid metabolism, may participate in iMN pathogenesis through key genes, including apolipoprotein A1 (APOA1), apolipoprotein B (APOB), apolipoprotein C3 (APOC3), cholesteryl ester transfer protein (CETP), and phospholipase A2 group XIIB (PLA2G12B). 31160422 2019
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.010 Biomarker disease BEFREE These data showed that HBV infection inhibits lipid metabolism and ApoC3 is negatively associated with HBV DNA load in HBeAg (-) CHB patients. 31186008 2019
CUI: C0267953
Disease: Necrosis of pancreas
Necrosis of pancreas
0.010 AlteredExpression disease BEFREE However, ApoC3-tg mice with the same triglyceride levels did not develop large areas of pancreatic necrosis, even upon the administration of poloxamer 407 to further increase triglyceride levels. 31570698 2019
CUI: C0524909
Disease: Hepatitis B, Chronic
Hepatitis B, Chronic
0.010 AlteredExpression disease BEFREE Serum apolipoprotein C3 levels are negatively associated with hepatitis B virus DNA in HBeAg-negative chronic hepatitis B patients. 31186008 2019
CUI: C1270972
Disease: Mild cognitive disorder
Mild cognitive disorder
0.010 AlteredExpression disease BEFREE Higher CSF APOC-III levels are significantly associated with slower cognitive decline over a 12-year period among individuals with MCI. 30689582 2019
CUI: C1392786
Disease: Cognitive changes
Cognitive changes
0.010 AlteredExpression phenotype BEFREE Plasma APOC-III levels showed a mild correlation with CSF APOC-III levels, but were not associated with longitudinal cognitive changes in the pooled sample or in diagnosis-stratified analyses. 30689582 2019
CUI: C3160761
Disease: Diabetic dyslipidaemia
Diabetic dyslipidaemia
0.010 Biomarker disease BEFREE Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia. 30972934 2019
Arteriosclerotic cardiovascular disease, NOS
0.010 Biomarker disease BEFREE The availability of specific ASOs lowering Lp(a) levels will allow rigorous testing of the Lp(a) hypothesis; by dramatically reducing plasma triglyceride levels, Volanesorsen (APOC3) and angiopoietin-like 3 (ANGPTL3)-LRx will further clarify the causality of triglyceride-rich lipoproteins in ASCVD. 31449975 2019
CUI: C0030305
Disease: Pancreatitis
Pancreatitis
0.010 Biomarker disease BEFREE An antisense oligonucleotide to apolipoprotein-C3, volanesorsen has been shown to decrease TGs by 70-80% and possibly to reduce rates of pancreatitis admissions. 29842811 2018
CUI: C0079773
Disease: Lymphoma, T-Cell, Cutaneous
Lymphoma, T-Cell, Cutaneous
0.010 GeneticVariation disease BEFREE These results indicate that the screening of APOA5 and APOC3 genotypes may be useful to estimate changes in triglyceride concentrations during bexarotene treatment in patients with CTCL and also to identify the best candidates for bexarotene therapy based on the expected adverse effect profile. 30422238 2018
CUI: C0333559
Disease: Infarction, Lacunar
Infarction, Lacunar
0.010 Biomarker disease BEFREE The ApoC-III enrichment of the HDL of patients with LACI may cause a reduction in the anti-inflammatory ability of HDL, which may contribute to the progression of the disease. 29115584 2018
CUI: C0339573
Disease: Glaucoma, Primary Open Angle
Glaucoma, Primary Open Angle
0.010 Biomarker disease BEFREE The most abundant proteins in POAG subjects are IGKC (13.56-fold), ITIH4 (4.1-fold), APOC3 (3.36-fold), IDH3A (3.11-fold), LOC105369216 (2.98-fold). 29847670 2018
CUI: C4476910
Disease: Thin-cap fibroatheroma
Thin-cap fibroatheroma
0.010 Biomarker phenotype BEFREE These indexes were independent predictors of the presence of TCFA (ΔApoB-48: odds ratio, 1.608; 95% confidence interval, 1.040-2.486; P=0.032; apolipoprotein C-III: odds ratio, 2.581; 95% confidence interval, 1.177-5.661; P=0.018). 29930008 2018
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.010 Biomarker disease BEFREE This study shows the relevance of polymorphisms in APOB (odds ratio (OR), 1.17; 95% confidence interval (95% CI), 0.74-1.85), APOC3 (OR, 1.33; 95% CI, 0.82-2.17) and APOE (OR, 1.75; 95% CI, 1.09-2.80), as genetic risk markers for hypercholesterolemia; polymorphisms in ACE (OR, 1.68; 95% CI, 0.32-8.77) and AGT (OR, 1.74; 95% CI, 0.97-3.14) for hypertension; and in APOE*3/*4 (OR, 2.06; 95% CI, 1.70-2.51) and APOE*4/*4 (OR, 3.08; 95% CI, 1.85-5.12) as unambiguous markers of dementia. 29081697 2017
CUI: C0019158
Disease: Hepatitis
Hepatitis
0.010 Biomarker group BEFREE These results indicate that apoCIII and/or hypertriglyceridemia plays a major role in liver inflammation and cell death, which in turn increases susceptibility to and the severity of diet-induced NAFLD. 28163820 2017
CUI: C0342335
Disease: insulin resistance in diabetes
insulin resistance in diabetes
0.010 Biomarker disease BEFREE In type-2 diabetes insulin resistance within the pancreatic islets leads to a local increase in apoCIII that promotes inflammation and β-cell dysfunction. 27875339 2017
CUI: C0497327
Disease: Dementia
Dementia
0.010 Biomarker disease BEFREE This study shows the relevance of polymorphisms in APOB (odds ratio (OR), 1.17; 95% confidence interval (95% CI), 0.74-1.85), APOC3 (OR, 1.33; 95% CI, 0.82-2.17) and APOE (OR, 1.75; 95% CI, 1.09-2.80), as genetic risk markers for hypercholesterolemia; polymorphisms in ACE (OR, 1.68; 95% CI, 0.32-8.77) and AGT (OR, 1.74; 95% CI, 0.97-3.14) for hypertension; and in APOE*3/*4 (OR, 2.06; 95% CI, 1.70-2.51) and APOE*4/*4 (OR, 3.08; 95% CI, 1.85-5.12) as unambiguous markers of dementia. 29081697 2017
CUI: C1257763
Disease: Overnutrition
Overnutrition
0.010 Biomarker phenotype BEFREE We concluded that APOC3, whose dysregulation is liable for hypertriglyceridemia, is not a predisposing factor for linking overnutrition to NAFLD in obesity. 28115523 2017
CUI: C2712907
Disease: obsolete Combined hyperlipidemia
obsolete Combined hyperlipidemia
0.010 AlteredExpression disease BEFREE PCSK9 significantly conferred prediction of both hypercholesterolemia and combined hyperlipidemia at a level of 235 ng/ml; apoC3 levels for hypertriglyceridemia, hypercholesterolemia and combined hyperlipidemia were 80.0, 71.5, and 86.4 μg/ml, respectively; and sdLDL-C for hypertriglyceridemia, hypercholesterolemia, combined hyperlipidemia and hypo high density lipoprotein (HDL) cholesterolemia 3.5, 2.5, 4.5, and 2.5 mg/dl, respectively (all p<0.001 for area under the receiver-operating characteristic curve). 27713142 2017
CUI: C0020459
Disease: Hyperinsulinism
Hyperinsulinism
0.010 Biomarker disease BEFREE ApoC3-transgenic mice, despite persistent hypertriglyceridemia, maintained euglycemia under both fed and fasting conditions without manifestation of insulin resistance and fasting hyperinsulinemia. 27226540 2016